These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 31494110)

  • 1. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
    Vardeny O
    Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
    Lu H; Meyer P; Hullin R
    Swiss Med Wkly; 2020 Aug; 150():w20341. PubMed ID: 32920793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
    Packer M
    Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: practical considerations and recommendations for cardiologists.
    Opingari E; Partridge ACR; Verma S; Bajaj HS
    Curr Opin Cardiol; 2018 Nov; 33(6):676-682. PubMed ID: 30148719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
    Evans M; Morgan AR; Yousef Z; Ellis G; Dashora U; Patel DC; Brown P; Hanif W; Townend JN; Kanumilli N; Moore J; Wilding JPH; Bain SC
    Drugs; 2021 Jul; 81(11):1243-1255. PubMed ID: 34160822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular benefit of SGLT2 inhibitors.
    Mohebi R; Januzzi JL
    Crit Rev Clin Lab Sci; 2022 May; 59(3):142-155. PubMed ID: 34784839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
    Engelhardt K; Ferguson M; Rosselli JL
    Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
    Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.